|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 141.70 BDT | +5.20% |
|
+13.18% | +38.79% |
| 03-05 | EARNINGS AND TRADING: CAB Payments rebuffs Helios bid approach | AN |
| 11-04 | Beximco Pharmaceuticals to Start Trading Under New Name | MT |
| Market Cap | 64.82B 528M 460M 426M 399M 748M 49.79B 753M 5.05B 1.96B 24.51B 1.98B 1.94B 85.09B | P/E 2025 * |
10.3x | P/E 2026 * | 9.14x |
|---|---|---|---|---|---|
| Enterprise Value | 64.82B 528M 460M 426M 399M 748M 49.79B 753M 5.05B 1.96B 24.51B 1.98B 1.94B 85.09B | EV / Sales 2025 * |
1.31x | EV / Sales 2026 * | 1.19x |
| Free-Float |
85.91% | Yield 2025 * |
3.53% | Yield 2026 * | 4.23% |
| 1 day | +5.20% | ||
| 1 week | +13.18% | ||
| Current month | +16.15% | ||
| 1 month | +19.18% | ||
| 3 months | +20.29% | ||
| 6 months | +32.06% | ||
| Current year | +38.79% |
| 1 week | 126.8 |  | 143 |
| 1 month | 120.8 | | 143 |
| Current year | 99.5 | | 143 |
| 1 year | 81.1 | | 143 |
| 3 years | 64.2 | | 146.2 |
| 5 years | 64.2 | | 255.4 |
| 10 years | 47.36 | | 255.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Iqbal Ahmed
CEO | Chief Executive Officer | - | 2024-03-03 |
| Director of Finance/CFO | 63 | 2002-12-31 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 2009-06-18 | |
| Director/Board Member | - | 2010-01-31 | |
Iqbal Ahmed
BRD | Director/Board Member | - | 1984-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.20% | +13.18% | +69.30% | -3.08% | 515M | |
| -1.21% | -3.04% | +44.03% | +143.07% | 980B | |
| -2.48% | -5.18% | +52.47% | +39.15% | 550B | |
| -2.14% | -4.94% | +16.83% | +57.08% | 382B | |
| +0.25% | -3.09% | +23.33% | +16.04% | 316B | |
| +0.61% | -1.69% | +27.35% | +13.73% | 272B | |
| +0.22% | -3.10% | +24.67% | +30.49% | 268B | |
| +4.59% | +1.98% | -38.43% | -46.26% | 199B | |
| -1.19% | -4.95% | +16.68% | +47.69% | 182B | |
| -1.35% | -1.46% | +14.06% | +59.26% | 154B | |
| Average | +0.25% | -1.49% | +25.03% | +35.72% | 330.28B | |
| Weighted average by Cap. | -0.78% | -3.67% | +29.49% | +63.30% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 49.63B 404M 352M 326M 305M 573M 38.12B 576M 3.87B 1.5B 18.76B 1.52B 1.48B 65.15B | 54.69B 445M 388M 359M 337M 631M 42B 635M 4.26B 1.65B 20.68B 1.67B 1.64B 71.79B |
| Net income | 6.14B 49.96M 43.56M 40.35M 37.77M 70.83M 4.71B 71.26M 479M 185M 2.32B 188M 184M 8.06B | 6.91B 56.21M 49.01M 45.39M 42.5M 79.7M 5.3B 80.18M 539M 209M 2.61B 211M 206M 9.07B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-18 | 141.70 BDT | +5.20% | 4,360,277 |
| 26-06-17 | 134.70 BDT | +1.81% | 1,980,755 |
| 26-06-16 | 132.30 BDT | +0.99% | 1,955,103 |
| 26-06-15 | 131.00 BDT | +3.72% | 2,640,862 |
| 26-06-14 | 126.30 BDT | +0.88% | 1,407,692 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- BXPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
